First Personal Financial Services decreased its stake in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 1.9% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 22,135 shares of the medical research company’s stock after selling 425 shares during the period. First Personal Financial Services’ holdings in Thermo Fisher Scientific were worth $4,188,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently modified their holdings of TMO. Proficio Capital Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 71.5% in the 1st quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock valued at $105,000 after acquiring an additional 253 shares in the last quarter. Chicago Partners Investment Group LLC purchased a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $108,000. Shine Investment Advisory Services Inc. purchased a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $113,000. Ropes Wealth Advisors LLC raised its holdings in shares of Thermo Fisher Scientific by 15.8% in the 2nd quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after acquiring an additional 97 shares in the last quarter. Finally, Atlantic Trust LLC purchased a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $138,000. 85.32% of the stock is currently owned by institutional investors and hedge funds.
Shares of Thermo Fisher Scientific Inc (NYSE TMO) traded up $0.75 during trading on Friday, hitting $193.51. The stock had a trading volume of 374,481 shares, compared to its average volume of 1,510,000. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81. The company has a market cap of $77,190.00, a price-to-earnings ratio of 21.26, a PEG ratio of 1.77 and a beta of 1.08. Thermo Fisher Scientific Inc has a 12-month low of $139.07 and a 12-month high of $201.20.
Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, beating the consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The firm had revenue of $5.12 billion for the quarter, compared to analyst estimates of $5.03 billion. During the same period in the prior year, the company earned $2.03 EPS. The company’s revenue was up 13.9% on a year-over-year basis. analysts expect that Thermo Fisher Scientific Inc will post 9.36 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be given a dividend of $0.15 per share. The ex-dividend date is Thursday, December 14th. This represents a $0.60 annualized dividend and a yield of 0.31%. Thermo Fisher Scientific’s payout ratio is 10.19%.
In related news, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the transaction, the chief executive officer now directly owns 252,577 shares in the company, valued at approximately $47,582,981.03. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Seth H. Hoogasian sold 4,140 shares of the firm’s stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $177.80, for a total value of $736,092.00. Following the transaction, the vice president now owns 25,518 shares in the company, valued at $4,537,100.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 60,420 shares of company stock worth $11,308,477. 0.49% of the stock is owned by corporate insiders.
Several analysts have weighed in on the company. Jefferies Group LLC reaffirmed a “hold” rating and issued a $195.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, September 28th. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $197.00 price target on the stock in a report on Tuesday, August 1st. BidaskClub cut Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Goldman Sachs Group Inc assumed coverage on Thermo Fisher Scientific in a report on Tuesday, September 26th. They issued a “buy” rating and a $225.00 price target on the stock. Finally, Barclays PLC reaffirmed an “overweight” rating and issued a $215.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Monday, September 25th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $205.71.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.